292 related articles for article (PubMed ID: 18936790)
1. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Quintás-Cardama A; Lazar AJ; Woodman SE; Kim K; Ross M; Hwu P
Nat Clin Pract Oncol; 2008 Dec; 5(12):737-40. PubMed ID: 18936790
[TBL] [Abstract][Full Text] [Related]
2. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
3. A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Knowles J; Lynch AC; Warrier SK; Henderson M; Heriot AG
Colorectal Dis; 2016 Sep; 18(9):877-82. PubMed ID: 26546509
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Egberts F; Gutzmer R; Ugurel S; Becker JC; Trefzer U; Degen A; Schenck F; Frey L; Wilhelm T; Hassel JC; Schadendorf D; Livingstone E; Mauch C; Garbe C; Berking C; Rass K; Mohr P; Kaehler KC; Weichenthal M; Hauschild A
Ann Oncol; 2011 Jul; 22(7):1667-1674. PubMed ID: 21220519
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Ott PA; Hamilton A; Min C; Safarzadeh-Amiri S; Goldberg L; Yoon J; Yee H; Buckley M; Christos PJ; Wright JJ; Polsky D; Osman I; Liebes L; Pavlick AC
PLoS One; 2010 Dec; 5(12):e15588. PubMed ID: 21206909
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in melanoma.
Mangana J; Levesque MP; Karpova MB; Dummer R
Expert Opin Investig Drugs; 2012 Apr; 21(4):557-68. PubMed ID: 22394203
[TBL] [Abstract][Full Text] [Related]
9. Complete response for advanced liver cancer during sorafenib therapy: case report.
Sacco R; Bargellini I; Gianluigi G; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Bertoni M; Capria A; Bresci G; Bartolozzi C
BMC Gastroenterol; 2011 Jan; 11():4. PubMed ID: 21241463
[TBL] [Abstract][Full Text] [Related]
10. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Eisen T; Ahmad T; Flaherty KT; Gore M; Kaye S; Marais R; Gibbens I; Hackett S; James M; Schuchter LM; Nathanson KL; Xia C; Simantov R; Schwartz B; Poulin-Costello M; O'Dwyer PJ; Ratain MJ
Br J Cancer; 2006 Sep; 95(5):581-6. PubMed ID: 16880785
[TBL] [Abstract][Full Text] [Related]
14. Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Castagneto B; Stevani I; Giorcelli L; Montefiore F; Bigatti GL; Pisacco P; Cosimi MF
Med Oncol; 2011 Dec; 28(4):1384-8. PubMed ID: 20552299
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Huynh H; Lee JW; Chow PK; Ngo VC; Lew GB; Lam IW; Ong HS; Chung A; Soo KC
Mol Cancer Ther; 2009 Jan; 8(1):152-9. PubMed ID: 19139124
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
18. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Bisagni G; Rossi G; Cavazza A; Sartori G; Gardini G; Boni C
J Thorac Oncol; 2009 Jun; 4(6):773-5. PubMed ID: 19461405
[TBL] [Abstract][Full Text] [Related]
19. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
So BJ; Bekaii-Saab T; Bloomston MA; Patel T
J Hematol Oncol; 2008 Oct; 1():18. PubMed ID: 18928548
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]